Clinical experience with @entity3118 in XXXX .

@entity1 @entity1261 @entity706 @entity10043 @entity5 @entity2590 @entity2592 @entity3052 @entity3118 @entity1778 @entity6444 @entity2359
@entity3118 (Fludara) is a new @entity10043 analogue that was first entered into clinical trials in 1982. Results of initial studies with high dosages (> 96 mg/m2/day for 5 to 7 days) of @entity3118 in acute @entity1778 showed significant cytoreductive activity but a high incidence of severe irreversible @entity2359 . The results of subsequent studies with lower dosages of 25 to 30 mg/m2/day for 5 days in @entity6444 ( @entity6444 ) and low grade @entity706 have shown this regimen to be effective and safe, with almost no significant @entity2359 . At present, the major role of @entity3118 in @entity1778 is in the management of @entity6444 . In previously treated @entity1 with @entity6444 , responses are obtained in more than 50% of @entity1 , with two-thirds of those responses being complete remissions according to the National @entity5 Institute Working Group (NCIWG) criteria for complete response and partial response. The major causes of morbidity associated with @entity3118 in @entity6444 are infections and febrile episodes. These occur more frequently in previously treated @entity1 and those with advanced stage of disease. Myelosuppression is dose limiting and a small proportion of @entity1 with @entity6444 develop moderate to severe and sometimes protracted myelosuppression. Administration of combined @entity3118 and @entity2592 ( @entity2592 ; @entity2592 ) alone (FA regimen) or together with @entity1261 (FLAG regimen) produced high response rates in previously treated refractory @entity1 with acute @entity1778 and previously untreated @entity1 with @entity3052 or @entity2590 . The wide range of biochemical and biological activities of @entity3118 suggests that it will have an expanding role in future combinations in the treatment of both @entity1778 .
